Paroxetine hydrochloride acetone solvate | 181237-74-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: Paroxetine hydrochloride acetone solvate
• 英文别名: (3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine;propan-2-one;hydrochloride
• CAS: 181237-74-1
• 化学式: C22H27ClFNO4
• 分子量: 423.9
• InChiKey: DPMHFUVLMMVQCA-YHOFXEKLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.34
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  56.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] PROCESS FOR THE PREPARATION OF PAROXETINE<br/>[FR] PROCEDE DE PREPARATION DE PAROXETINE
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO2001029031A1

  公开（公告）日：2001-04-26

  Three process schemes (1), (2) and (3) for a complete route to paroxetine from a pyridine ester are disclosed.

  披索西汀从吡啶酯完整路线的三种工艺方案（1）、（2）和（3）被披露。
• New forms of paroxetin hydrochloride
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1136490A1

  公开（公告）日：2001-09-26

  1. The present invention relates to paroxetine hydrochloride anhydrate substantially free of bound propan-2-ol, several forms of the above, processes for preparing the above, new intermediates useful in preparing the above and methods of treating and/or preventing certain diseases by administering the compounds of the invention to a sufferer in need thereof.

  本发明涉及基本上不含结合丙-2-醇的盐酸帕罗西汀水合物、上述物质的几种形式、制备上述物质的工艺、用于制备上述物质的新中间体，以及通过向有需要的患者施用本发明化合物来治疗和/或预防某些疾病的方法。
• A process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1321465A2

  公开（公告）日：2003-06-25

  Paroxetine hydrochloride propan-2-ol solvate is desolvated to remove propan-2-ol and prepare paroxetine hydrochloride anhydrate by heating the solvate mass and increasing the temperature of the heating as the amount of propan-2-ol remaining in the solvate mass decreases.

  对盐酸帕罗西汀丙-2-醇溶胶进行脱溶，除去丙-2-醇，制备盐酸帕罗西汀水合物，方法是加热溶胶块，随着溶胶块中残留的丙-2-醇量的减少，提高加热温度。
• Various forms of paroxetine hydrochloride anhydrate
  申请人：SMITHKLINE BEECHAM PLC

  公开号：EP1378508A1

  公开（公告）日：2004-01-07

  The present invention relates to paroxetine hydrochloride anhydrate substantially free of bound propan-2-ol, several forms of the above, and specifically processes for preparing the above comprising crystallising paroxetine hydrochloride in an organic solvent or mixture of organic solvents which form a solvate with the paroxetine hydrochloride and which are not removable by conventional vacuum oven drying techniques and thereafter displacing the solvated solvent or solvents using a displacing agent.

  本发明涉及基本上不含结合丙-2-醇的盐酸帕罗西汀水合物、上述物质的几种形式，特别是制备上述物质的工艺，包括在有机溶剂或有机溶剂混合物中使盐酸帕罗西汀结晶，这些有机溶剂与盐酸帕罗西汀形成溶解物，并且不能通过常规真空烘箱干燥技术去除，然后使用置换剂置换溶解的溶剂。
• Novel compounds
  申请人：SmithKline Beecham Corporation

  公开号：US20030004188A1

  公开（公告）日：2003-01-02

  Invented is paroxetine hydrochloride anhydrate in Form B and paroxetine hydrochloride anhydrate in Form D. Also invented are pharmaceutical formulations comprising these compounds and methods of using these compounds in therapy.

  发明了盐酸帕罗西汀水合物 B 型和盐酸帕罗西汀水合物 D 型，还发明了包含这些化合物的药物制剂和使用这些化合物进行治疗的方法。